-
公开(公告)号：KR1020140046294A
公开(公告)日：2014-04-18
申请号：KR1020120112595
申请日：2012-10-10
Applicant: 부경대학교 산학협력단
IPC: A61K31/19 , A61K31/185 , A61P29/00
CPC classification number: A61K31/192 , A23L33/105 , A23V2002/00 , Y02A50/40 , Y02A50/401 , A23V2200/314 , A23V2200/316 , A23V2250/02
Abstract: The present invention relates to a composition comprising veratric acid as an active ingredient for preventing or treating inflammatory diseases. The veratric acid according to the present invention has an excellent effect of inhibiting production of nitric oxide and has an excellent activity of inhibiting phosphorylation of MAPK, NF-κB, GSK-3β, and c-Raf in a macrophage cell stimulated by a stimulation factor that causes in inflammatory reaction. Thus, the veratric acid can be used for development of medicines for treating the inflammatory diseases which can be caused by excessive inflammatory reactions. Further, the veratric acid of the present invention does not induce toxicity to cells and is stable in the body; thereby the veratric acid can be used as a material or a functional health food capable of preventing or alleviating the inflammatory diseases.
Abstract translation: 本发明涉及包含维生素酸作为预防或治疗炎性疾病的活性成分的组合物。 根据本发明的枸橼酸具有抑制一氧化氮产生的优异效果，并且在由刺激因子刺激的巨噬细胞中抑制MAPK，NF-κB，GSK-3β和c-Raf磷酸化的优异活性 导致炎症反应。 因此，维生素酸可用于开发用于治疗可由过度炎症反应引起的炎性疾病的药物。 此外，本发明的维生素酸不诱导细胞毒性，在体内稳定; 从而可以将藜芦酸用作能够预防或减轻炎性疾病的材料或功能保健食品。
-
公开(公告)号：KR1020140040359A
公开(公告)日：2014-04-03
申请号：KR1020120106857
申请日：2012-09-26
Applicant: 부경대학교 산학협력단
IPC: A61K31/4709 , A61K36/62 , A61P35/00
CPC classification number: A61K36/62 , A61K31/4725
Abstract: The present invention relates the use of neferine for treating liver cancer and, more specifically, to a pharmaceutical composition and health functional foods containing the neferine as an active ingredient for preventing or treating liver cancer. The neferine in the present invention has an anticancer effect by stopping the cell cycle of liver cancer cells, inducing apoptosis and autophagy, and inhabiting vascularization and cell migration. Particularly, the neferine shows specific cytotoxicity on the viral infection-mediated liver cancer cells, thereby having an optimum therapeutic effect against the liver cancer induced by viral infection. Thus, the neferine in the present invention can be used as the pharmaceutical composition and health functional food, as an ingredient for preventing or treating the liver cancer, thereby being expected to be of good value in case of applying in the food or pharmaceutical industry. Also, the composition containing the neferine as the active ingredient in the present invention is safe to use for a long time since the neferine shows no cytotoxicity except the specific liver cancer cells.
Abstract translation: 本发明涉及炔诺酮用于治疗肝癌的用途，更具体地，涉及含有神经纤维作为预防或治疗肝癌的活性成分的药物组合物和保健功能性食品。 本发明中的炔诺酮通过停止肝癌细胞的细胞周期，诱导细胞凋亡和自噬，并且维持血管形成和细胞迁移，具有抗癌作用。 特别地，neferine对病毒感染介导的肝癌细胞表现出特异性细胞毒性，从而对由病毒感染诱导的肝癌具有最佳治疗效果。 因此，本发明中的炔诺酮可以作为药物组合物和保健功能性食品而使用，作为预防或治疗肝癌的成分，因此在应用于食品或制药工业的情况下被认为具有良好的价值。 此外，本发明中含有作为活性成分的炔诺酮的组合物长时间使用是安全的，因为除了特定的肝癌细胞之外，neferine不显示细胞毒性。
-
公开(公告)号：KR101576126B1
公开(公告)日：2015-12-11
申请号：KR1020140191757
申请日：2014-12-29
Applicant: 부경대학교 산학협력단
Abstract: 본발명은서열번호 1로기재되는아미노산서열로구성되는펩타이드를유효성분으로함유하는, 비만예방및 치료용약학조성물을제공한다.
Abstract translation: 本发明涉及一种新的药物组合物，其包含αAL14肽作为预防和治疗肥胖症的活性成分，更具体地，涉及包含由SEQ ID NO：1所示的氨基酸序列组成的肽的药物组合物。 1作为预防和治疗肥胖的活性成分。
-
-
Patent Agency Ranking
公开(公告)号：KR101973860B1
公开(公告)日：2019-04-29
申请号：KR1020170098288
申请日：2017-08-02
Applicant: 부경대학교 산학협력단
IPC: A61K8/9789 , A23L33/00 , A23L33/105 , A23L7/152 , A61Q19/02
-
公开(公告)号：KR101747044B1
公开(公告)日：2017-06-14
申请号：KR1020160111087
申请日：2016-08-30
Applicant: 부경대학교 산학협력단
IPC: C07D513/14 , A61K31/54 , A61K36/06 , A23L1/30
CPC classification number: C07D513/14 , A23L33/10 , A23V2002/00 , A23V2200/308 , A23V2250/208 , A61K31/54 , A61K36/06
Abstract: 본발명은신규한크리스타진(cristazine) 화합물을함유하는암 예방또는치료용약학적조성물에관한것으로, 본발명에따른신규한크리스타진(cristazine) 화합물은정상세포에대한세포독성은거의없으면서, 특정암세포(피부암, 자궁경부암, 간암)에대한세포독성은매우높으므로, 특정암의치료제로유용할수 있다.
Abstract translation: 本发明涉及含有吖啶化合物的新型癌症预防或治疗药物组合物，并且本发明的新型吖啶化合物的特征在于其对正常细胞的细胞毒性小， （皮肤癌，宫颈癌，肝癌）非常高，因此可用作特定癌症的治疗剂。
-
公开(公告)号：KR101418746B1
公开(公告)日：2014-08-13
申请号：KR1020120112595
申请日：2012-10-10
Applicant: 부경대학교 산학협력단
IPC: A61K31/19 , A61K31/185 , A61P29/00
CPC classification number: A61K31/192 , A23L33/105 , A23V2002/00 , Y02A50/40 , Y02A50/401 , A23V2200/314 , A23V2200/316 , A23V2250/02
Abstract: 본 발명은 베라트르산을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물에 관한 것으로서, 본 발명에 따른 베라트르산은 염증반응을 유발시키는 자극인자에 의한 대식세포에서 산화질소 생성 억제 효과가 우수하고, 염증성 사이토카인인 IL-1β의 생성을 억제하는 효과가 우수하며, MAPK, NF-κB, GSK-3β, c-Raf의 인산화를 억제하는 효과가 우수하여 과다한 염증반응으로 유발될 수 있는 염증질환의 치료제 개발에 유용하게 사용될 수 있다. 또한 본 발명에 따른 베라트르산은 세포에 독성을 유발하지 않기 때문에 체내 안정한 특징이 있어 염증질환을 예방 또는 개선할 수 있는 기능성 건강식품의 소재로도 사용할 수 있는 효과가 있다.
-
公开(公告)号：KR101418161B1
公开(公告)日：2014-07-09
申请号：KR1020120106857
申请日：2012-09-26
Applicant: 부경대학교 산학협력단
IPC: A61K31/4709 , A61K36/62 , A61P35/00
CPC classification number: A61K36/62 , A61K31/4725
Abstract: 본 발명은 네퍼린(neferine)의 간암 치료의 신규 용도에 관한 것으로, 자세하게는 네퍼린을 유효성분으로 포함하는 간암 예방 또는 치료용 약제학적 조성물, 건강기능식품에 관한 것이다. 본 발명의 네퍼린(Neferine)은 간암세포의 세포주기중지, 세포사멸(apoptosis) 유도, 자가포식(autophagy) 유도, 신생혈관형성 억제 및 세포이동 억제 활성을 통해 항암 효과를 가질 수 있다. 특히, 네퍼린은 간암세포 중에서도 바이러스감염에 의해 유발된 간암세포에 특이적으로 세포독성을 가짐에 따라, 바이러스감염에 의해 유발된 간암세포에 최적화된 치료효과를 가진다. 따라서 본 발명의 네퍼린은 간암을 예방 또는 치료할 수 있는 물질로서 약리학적 조성물과 같은 의약품은 물론이고, 건강기능식품 등으로 활용할 수 있어 식품산업 및 의약산업에 응용될 경우 그 가치가 매우 높을 것으로 기대된다. 또한 본 발명의 네퍼린(Neferine)은 특정 간암세포 외에는 세포독성을 보이지 않기 때문에, 이를 유효성분으로 포함하는 본 발명의 조성물은 장기적 사용에도 안전한 이점을 가진다.
-
19.发明公开
公开(公告)号：KR1020140065215A
公开(公告)日：2014-05-29
申请号：KR1020120132468
申请日：2012-11-21
Applicant: 부경대학교 산학협력단
IPC: C07D211/74 , A61K31/4418 , A61P35/00
CPC classification number: A61K31/4418 , C07D211/74 , C07D211/78
Abstract: The present invention relates to a novel (new) tetrahydropyridinol derivative compound and a new use thereof for cancer treatment, and more specifically, to a novel tetrahydropyridinol derivative compound, a pharmaceutical composition comprising the same as an active ingredient for preventing or treating cancer, and a health functional food. The novel tetrahydropyridinol derivative compound of the present invention can inhibit the proliferation and invasion of cancer cells by a wnt/β-catenin signal inhibition mechanism through down-regulation of β-catenin expression, up-regulation of glycogen synthase kinase 3-β (GSK-3β), or up-regulation of E-cadherin expression, and also induce cell cycle arrest of cancer cells through the inhibition of CDK2 expression and the increase of p21 and p27 expression. Therefore, the novel tetrahydropyridinol derivative of the present invention can be applied to medicine, such as a pharmaceutical composition, as well as a health function food, as a material which can prevent or treat cancer, and thus is expected to have a very high value when being applied to food industries and medicinal industries. Further, since the novel tetrahydropyridinol derivative of the present invention does not show cytotoxicity to non-tumor cells instead of cancer cells, the composition of the present invention comprising the derivative as an active ingredient has an advantage of being safe even for long-term use.
Abstract translation: 本发明涉及一种新的（新）四氢吡啶醇衍生物化合物及其用于癌症治疗的新用途，更具体地，涉及一种新的四氢吡啶醇衍生物化合物，包含其作为预防或治疗癌症的活性成分的药物组合物，以及 健康功能食品。 本发明的新型四氢吡啶醇衍生物可通过下调β-连环蛋白表达，糖原合酶激酶3-β（GSK）的上调，通过wnt /β-连环蛋白信号抑制机制抑制癌细胞的增殖和侵袭 -3β）或E-钙粘蛋白表达的上调，并通过抑制CDK2表达和p21和p27表达的增加诱导癌细胞的细胞周期停滞。 因此，本发明的新型四氢吡啶醇衍生物可以用作药物，例如药物组合物，以及健康功能食品，作为可以预防或治疗癌症的材料，因此预期具有非常高的价值 适用于食品工业和医药行业。 此外，由于本发明的新型四氢吡啶醇衍生物不代表癌细胞对非肿瘤细胞没有显示细胞毒性，所以包含该衍生物作为活性成分的本发明的组合物具有即使长期使用也是安全的优点 。
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.026 seconds)
